Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Biotage AB (publ) (PQX1.F)

Compare
10.00
-0.18
(-1.77%)
At close: February 28 at 8:12:59 AM GMT+1
Loading Chart for PQX1.F
DELL
  • Previous Close 10.18
  • Open 10.00
  • Bid 9.79 x 260000
  • Ask 10.17 x 260000
  • Day's Range 10.00 - 10.00
  • 52 Week Range 9.64 - 17.33
  • Volume 19
  • Avg. Volume 4
  • Market Cap (intraday) 809.512M
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) 31.25
  • EPS (TTM) 0.32
  • Earnings Date Apr 24, 2025
  • Forward Dividend & Yield 0.14 (1.37%)
  • Ex-Dividend Date Apr 26, 2024
  • 1y Target Est --

Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, diagnostics, clinical, environmental protection, food safety, clinical, forensic, and academic laboratories industries. It operates in more than 80 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.

www.biotage.com

673

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PQX1.F

View More

Performance Overview: PQX1.F

Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

PQX1.F
29.43%
OMX Stockholm 30 Index
9.73%

1-Year Return

PQX1.F
24.84%
OMX Stockholm 30 Index
11.57%

3-Year Return

PQX1.F
3.17%
OMX Stockholm 30 Index
27.23%

5-Year Return

PQX1.F
40.35%
OMX Stockholm 30 Index
58.27%

Compare To: PQX1.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PQX1.F

View More

Valuation Measures

Annual
As of 2/28/2025
  • Market Cap

    797.72M

  • Enterprise Value

    781.27M

  • Trailing P/E

    31.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.36

  • Price/Book (mrq)

    2.18

  • Enterprise Value/Revenue

    4.25

  • Enterprise Value/EBITDA

    15.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.81%

  • Return on Assets (ttm)

    4.77%

  • Return on Equity (ttm)

    7.31%

  • Revenue (ttm)

    2.06B

  • Net Income Avi to Common (ttm)

    284M

  • Diluted EPS (ttm)

    0.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    434M

  • Total Debt/Equity (mrq)

    6.08%

  • Levered Free Cash Flow (ttm)

    26M

Research Analysis: PQX1.F

View More

Company Insights: PQX1.F

Research Reports: PQX1.F

View More

People Also Watch